Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
National University Corporation Kumamoto University has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units, showing that the university's research is being evaluated by multiple specialized groups. The 5 pending actions are assigned to 5 distinct examiners, creating a diverse set of individual reviews. This variety in examiners suggests that the university's patent strategy must account for multiple perspectives.
CELESTE A RONEY is the busiest examiner for this portfolio, with 1 pending action. The presence of 5 distinct examiners for 5 actions means that no single examiner has a dominant influence over the current pending portfolio. The 2 distinct art units involved suggest that while the examiners are different, the prosecution environment is limited to two specific administrative divisions within the USPTO. Handling 5 pending office actions across 2 distinct art units allows the university to develop specialized expertise in those specific areas.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| PARIHAR, SUCHIN | 1 | 87.8% | +8.9% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443355 | PROGRAMMABLE LOGIC DEVICE AND METHODS OF IMPLEMENTING LOGIC CIRCUITS TO IT | PARIHAR, SUCHIN | — |
| 18560182 | METALLO-BETA-LACTAMASE INHIBITOR | VARADARAJ, ARCHANA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708460 | THERAPEUTIC AGENT FOR REFRACTORY VIRAL INFECTIONS | RONEY, CELESTE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258529 | Cyclic Single-Chain Antibody | FAUST, AMBER KATHLEEN | 5d |
| 18708460 | THERAPEUTIC AGENT FOR REFRACTORY VIRAL INFECTIONS | RONEY, CELESTE A | — |
| 18560182 | METALLO-BETA-LACTAMASE INHIBITOR | VARADARAJ, ARCHANA | — |
| 18131450 | TRANSTHYRETIN TETRAMER STABILIZING AGENT, AND PREVENTING AGENT OR PROGRESSION SUPPRESSING AGENT FOR TRANSTHYRETIN AMYLOIDOSIS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708460 | THERAPEUTIC AGENT FOR REFRACTORY VIRAL INFECTIONS | RONEY, CELESTE A | — | §103§112 | Non-Final OA | — | Pending | Jan 28, 2025 |
| 18443355 | PROGRAMMABLE LOGIC DEVICE AND METHODS OF IMPLEMENTING LOGIC CIRCUITS TO IT | PARIHAR, SUCHIN | — | §102 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18560182 | METALLO-BETA-LACTAMASE INHIBITOR | VARADARAJ, ARCHANA | — | §103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18131450 | TRANSTHYRETIN TETRAMER STABILIZING AGENT, AND PREVENTING AGENT OR PROGRESSION SUPPRESSING AGENT FOR TRANSTHYRETIN AMYLOIDOSIS | HUI, SAN MING R | 1627 | §103 | Final Rejection | — | Pending | Apr 06, 2023 |
| 17258529 | Cyclic Single-Chain Antibody | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | 5d | Pending | Jan 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial